Johnson & Johnson vs. Moleculin Biotech, Inc.
Johnson & Johnson (JNJ) comes out ahead, leading on 5 of 6 compared factors.
Size & Scale
| JNJ | MBRX | |
|---|---|---|
| Market Cap | $627.42 billion | $4.35 million |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | $-40,501,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | MBRX | |
|---|---|---|
| P/E Ratio | 30.20 | — |
| Price / Book | 7.38 | 0.29 |
| Price / Sales | 6.41 | — |
MBRX leads on 1 of 1 valuation factors.
Profitability
| JNJ | MBRX | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | -266.75% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| JNJ | MBRX | |
|---|---|---|
| Dividend Yield | 2.06% | — |
| Payout Ratio | 62.18 | — |
JNJ and MBRX split the dividend factors evenly.
Risk & Sentiment
| JNJ | MBRX | |
|---|---|---|
| Short Interest | 0.67% | 21.18% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, MBRX overview, MBRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.